Enanta Pharma (ENTA) Misses Q4 EPS by 51c

Enanta Pharma (NASDAQ: ENTA) reported Q4 EPS of ($1.46), $0.51 worse than the analyst estimate of ($0.95). Revenue for the quarter came in at $23.6 million versus the consensus estimate of $25.74 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• AXT appoints Tracy Liu to its board of directors
• Credo Technology pops 3.5% as Evercore initiates with monster $325 price target